Kensington, MD, United States of America

Wataru Akahata

This inventor holds 24 USPTO granted patents and 13 published patent applications, plus 3 CIPO patents and 6 EPO patents, primarily in Immunotherapy Development. Top assignees: Vlp Therapeutics, LLC, The United States of America, as Represented by the Secretary, Department of Health and Human Services, Vlp Theranentics. Inc.. Active years: 2016-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Wataru Akahata. Retrieved from https://idiyas.com/inventor/wataru-akahata

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 24 (Patent Applications = 13)

% Patents Active = 91.7

CIPO Patents = 3 (Patent Applications = 3)

EPO Patents = 6 (Patent Applications = 15)

Average Co-Inventor Count = 2.3

ph-index = 6

Forward Citations = 109(Granted Patents)

Company Filing History:

12 out of 12

Vlp Therapeutics, LLC

patents

10 out of 3,693

The United States of America, as Represented by the Secretary, Department of Health and Human Services

patents

1 out of 1

Vlp Theranentics. Inc.

patent

4. 1 out of 1

Vlp Thereapeutics, LLC

patent

Years Active: 2016-2026

Loading Chart...

Areas of Expertise:

Cytokine Immunotherapy

Virus-Like Particles

Chikungunya Virus

Alphavirus Replicon

Immune Response Modulation

Antigen Targeting

Venezuelan Equine Encephalitis

Malaria Vaccine

Structural Proteins

VLP Production

Therapeutic Applications

Chimeric Antigens

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12742182 - CYTOKINE IMMUNOTHERAPY (2026-09-22),

2. 12636341 - GALECTIN-TARGETING IMMUNOTHERAPY (2026-05-26),

3. 12281336 - Chikungunya virus (CHIKV) virus-like particles (VLPS) comprising the C, E1, and E2 structural proteins (2025-04-21),

4. 12280102 - Alphavirus replicon encoding chimeric SARS-CoV-2 receptor binding domains (2025-04-21),

5. 12227770 - Alphavirus replicon particle (2025-02-18),

6. 12168675 - Virus-like particles and methods of use (2024-12-17),

7. 12134777 - Alphavirus replicon vector and immunotherapy by administering same (2024-11-05),

8. 11992523 - Method for producing chikungunya virus (CHIKV) virus-like particles comprising the C, E2, and E1 structural proteins (2024-05-28),

9. 11718647 - Virus-like particles and methods of use (2023-08-08),

10. 11369674 - Treatment method utilizing chikungunya virus (CHIKV) virus-like particles (VLPS) comprising the C, E2 and E1 structural proteins (2022-06-28),

11. 11345726 - Chikungunya virus (CHIKV) or Venezuelan equine encephalitis virus (VEEV) virus-like particles comprising heterologous antigens inserted into the envelope protein (2022-05-31),

12. 11098084 - Virus-like particles and methods of use (2021-08-24),

13. 10464986 - Virus like particle comprising PD-1 antigen or PD-1 ligand antigen (2019-11-05),

14. 10385101 - Virus like particle comprising modified envelope protein E3 (2019-08-20),

15. 10369208 - Methods for the induction of immune responses in a subject compromising administering virus-like particles (VLPS) prepared from Chikungunya virus structural proteins (2019-08-06),

Title: Innovations by Wataru Akahata: Pioneering Alphavirus Research

Introduction

Wataru Akahata is an accomplished inventor based in Kensington, MD, who has contributed significantly to the field of medical research with a portfolio of 20 patents. His innovative work primarily focuses on the development of alphavirus replicon particles and virus-like particles, which hold promise in the prevention and treatment of viral diseases.

Latest Patents

One of Akahata's notable inventions is the "Alphavirus replicon particle," which includes alphavirus structural proteins and a replicon comprising polynucleotides encoding essential non-structural proteins. This invention strategically alters specific amino acids in the viral envelope to enhance its efficacy.

Additionally, he has developed innovative "Virus-like particles and methods of use," which feature modified alphavirus and flavivirus virus-like particles. This invention outlines various methods and compositions for producing these modified particles, aimed at delivering therapeutic agents effectively to cells and improving treatment outcomes related to alphavirus and flavivirus-mediated diseases.

Career Highlights

Throughout his career, Akahata has made significant contributions while working for prestigious organizations such as the United States of America, as represented by the Secretary, Department of Health and Human Services, and VLP Therapeutics, LLC. His research and inventions have positioned him as a key figure in viral research and therapeutic development.

Collaborations

Akahata has collaborated with several talented professionals in his field, including Ryuji Ueno and Srinivas Rao. These collaborations have facilitated breakthrough advancements in his innovative projects and have broadened the impact of his research within the scientific community.

Conclusion

Wataru Akahata's innovative contributions to the fields of virology and therapeutic development underscore the importance of continuous research in combating viral diseases. With a strong portfolio of patents, he remains at the forefront of medical advancements, helping to pave the way for future innovations in viral treatment and prevention.

Profile summary based on public USPTO records.